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ABSTRACT
SPBP (Stromelysin-1 PDGF responsive element
binding protein) is a ubiquitously expressed
220kDa nuclear protein shown to enhance or
repress the transcriptional activity of various tran-
scription factors. A yeast two-hybrid screen, with
the extended plant homeodomain (ePHD) of
SPBP as bait, identified TopBP1 (topoisomerase II
b-binding protein 1) as a candidate interaction
partner of SPBP. TopBP1 has eight BRCA1 carboxy-
terminal (BRCT) domains and is involved in DNA
replication, DNA damage responses and in the
regulation of gene expression. The interaction
between SPBP and TopBP1 was confirmed in vitro
and in vivo, and was found to be mediated by the
ePHD domain of SPBP and the BRCT6 domain of
TopBP1. Both SPBP and TopBP1 enhanced
the transcriptional activity of Ets1 on the c-myc
P1P2- and matrix metalloproteinase-3 (MMP3)
promoters. Together they displayed a more than
additive effect. Both proteins were associated with
these promoters. The involvement of TopBP1 was
dependent on the serine 1159 phosphorylation site,
known to be important for transcriptional activation.
Depletion of endogenous SPBP by siRNA treatment
reduced MMP3 secretion by 50% in phorbol
ester-stimulated human fibroblasts. Taken together,
our results show that TopBP1 and SPBP interact
physically and functionally to co-operate as
co-activators of Ets1.
INTRODUCTION
Stromelysin-1 PDGF responsive element binding protein
(SPBP) is a 220kDa ubiquitously expressed nuclear
protein containing an N-terminal transactivation
domain, three nuclear localisation signals, a DNA-binding
domain with an AT-hook and a C-terminal extended
PHD domain (ePHD) (Figure 1A) (1). Originally, SPBP
was identiﬁed as a protein involved in transcriptional
activation of the matrix metalloproteinase-3 (MMP3)/
Stromelysin-1 promoter via the speciﬁc sequence element
SPRE (Stromelysin-1 PDGF responsive element) (2).
Later SPBP was found to act as a transcriptional
co-activator since it enhanced the transcriptional activity
of the positive co-factor and RING ﬁnger protein
SNURF/RNF4 (3), and of certain transcription factors
such as Sp1, Ets1, Pax6 and c-Jun (1). SPBP was also
reported to interact with c-Jun in vitro (4). Recently, SPBP
was found to act as a phosphoserine-speciﬁc repressor
of oestrogen receptor a (ERa) (5). A region spanning
NLS2 of SPBP (Figure 1A) bound directly to ERa
phosphorylated on serine 104, 106 and 118, but not to
the unphosphorylated form of ERa. Over-expression of
SPBP inhibited the proliferation of an ERa-dependent
breast cancer cell line (5). Thus, a picture is emerging
of SPBP as a transcriptional co-regulator with both
activating and inhibitory potential depending on the
conditions.
The PHD ﬁnger is a common structural motif present
throughout eukaryotic proteomes in nuclear, chromatin-
associated proteins (6,7). PHD ﬁngers are found to
have both protein- and nucleosome-binding activity (7),
and recently it was shown that the PHD ﬁnger is a highly
specialized methyl-lysine-binding domain recognizing
trimethylated lysine 4 on histone H3 (8). PHD ﬁngers
may co-operate with an adjacent domain to constitute a
functional nucleosome-binding module (9,10). The ePHD
domain of SPBP is related to the PHD ﬁnger motif.
The PHD domains contain two zinc-ﬁngers with the zinc
ligands forming a Cys4-His-Cys3 signature. The ePHD
domain has instead a Cys4-His-Cys2-His signature and
an N-terminal extension that may form an additional
zinc-ﬁnger with a Cys2-His-Cys signature.
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mediator that binds to ATR (ataxia-telangiectasia
and Rad3 related) and is a direct positive regulator of
the ATR–ATRIP complex upon DNA damage (11).
TopBP1 is recruited to sites of DNA damage and
replication stress via its interaction with Rad9 (12,13).
TopBP1, ﬁrst identiﬁed as an interaction partner of
topoisomerase II b (14), is associated with chromatin
during DNA replication and important for genome
integrity during normal S-phase (15). In addition to its
roles in checkpoint signalling and genome maintenance,
several reports implicate TopBP1 in transcriptional regula-
tion. Metazoan TopBP1 contains ﬁve BRCT domains
homologous to yeast Dpb11 (Saccharomyces cerevisiae)
and Cut5/Rad4 (Schizosaccharomyces pombe), and three
additionalBRCTdomainsintheC-terminusthatarefound
to interact with various transcription factors such as E2F1
(16), Miz-1 (17) and human papillomavirus type 16
(HPV16) transcription-replication factor E2 (18). Over-
expressionof TopBP1enhancedthe ability ofHPV16 E2to
activate transcription and replication (18), while the Miz-1-
TopBP1 interaction inhibited Miz-1’s ability to activate its
target genes p15INK4B and p21Cip1 (17). TopBP1 inter-
acts with E2F1 via its BRCT6 domain and recruits the
chromatin modiﬁcation complex Brg/BRM1 leading to
repression of known E2F1 activities, including transcrip-
tional activation and induction of apoptosis (16,19). This
interactionis observed bothafter DNA damage andduring
G1/S transition, and believed to be crucial for the control
of E2F1-dependent apoptosis. The interaction between
TopBP1 and the three transcription factors HPV16 E2,
Miz-1 and E2F1 involves the phosphoinositide 3-kinase
(PI3K)—Akt/PKB signalling pathway (20). Akt/PKB
Figure 1. SPBP and TopBP1 interact in vitro via the ePHD and BRCT6
domains. (A) Schematic representation of the domain structure of
human SPBP (1960 amino acids) and human TopBP1 (1522 amino
acids). Deletion mutants of SPBP and TopBP1 used in this study and
the TopBP1 region isolated in the yeast two-hybrid screen are
indicated. The eight BRCT domains of TopBP1 are represented by
numbered boxes. The open boxes designated A-G of SPBP represent
regions with strong homology to human RAI1. TAD: trans-activation
domain, DBD: DNA-binding domain, NLS: Nuclear Localization
Signal, ePHD: extended PHD domain, Q1/Q2: Glutamine-rich stretches.
(B) In vitro co-immunoprecipitation showing interaction between SPBP
and TopBP1 full-length proteins. Full-length HA-TopBP1 was in vitro
co-translated together with Myc-SPBP in the presence of [
35S]methionine.
Immunoprecipitations were performed using an anti-HA antibody.
Precipitated proteins as well as 10% input of in vitro translated
proteins were resolved by SDS–PAGE (5%). Negative control is the
HA-tag co-translated together with Myc-tagged full-length SPBP
and immunoprecipitated with an anti-HA antibody. (C) GST pull-
down assays demonstrating interaction both between the complete
ePHD and the ePHD(3–12) domain of SPBP, and TopBP1(862–1406).
HA-tagged TopBP1(862–1406) was in vitro translated in the presence
of [
35S]methionine and incubated with equal amounts of either GST,
GST-SPBP(ePHD) or GST-SPBP(ePHD3-12). The pulled down proteins,
together with in vitro translated HA-TopBP1(862–1406) corresponding to
10% of the input were separated by SDS–PAGE (10%). (D) BRCT6
domain of TopBP1 binds strongly to SPBP, while BRCT7+8 shows
weak aﬃnity for SPBP. Radiolabelled in vitro translated full-length
HA-SPBP was allowed to bind to equal amounts of the diﬀerent GST-
fused fragments of TopBP1. The interaction between TopBP1(862–1406)
and full-length HA-SPBP was tested with, or without the nuclease
benzonase. Samples and 10% of the input were resolved by SDS–PAGE
(5%). (E and F) In vitro GST pull-down assays demonstrating that
the SPBP(1333–1666) region interacts weakly with TopBP1.
HA-tagged SPBP, SPBP(ePHD), SPBP(4–486), SPBP(532–1344) and
SPBP(1333–1666) were in vitro translated in the presence of
[
35S]methionine and incubated with equal amounts of either GST
or GST-TopBP1(BRCT6). The pulled-down proteins, together with
10% of the input were separated by SDS–PAGE.
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merization of TopBP1, which is crucial for the observed
interactions. Additionally, TopBP1 is reported to interact
with the tyrosine kinase c-Abl (21). TopBP1 was demon-
stratedto be phosphorylated byc-Abl, andto repress c-Abl
at the level of transcription, probably by recruiting histone
deacetylasestothec-ablpromoter.Similartotherepression
activity involving E2F and Miz-1, the repression of the
c-abl promoter is dependent on phosphorylation.
Here we show that TopBP1 and SPBP interact in vitro
and in vivo. The interaction involved mainly the ePHD
domain of SPBP and the BRCT6 domain of TopBP1.
Reporter gene assays using the Ets1 regulated promoters
c-myc P1P2 and MMP3, showed that TopBP1 and SPBP
co-operate to enhance Ets1-mediated transcription. This
co-operation requires their interaction domains and is
dependent on the S1159 phosphorylation site of TopBP1.
Both TopBP1 and SPBP were found to be associated with
the c-myc P1P2 promoter and the MMP3 promoter.
Mutation of the Ets1-binding sites in the MMP3 promoter
inhibited the stimulatory eﬀect of Ets1, SPBP and
TopBP1. Finally, siRNA mediated knockdown of endo-
genous SPBP signiﬁcantly reduced the expression of the
metalloproteinase MMP3 in a human ﬁbroblast cell line.
MATERIALS AND METHODS
Plasmids
cDNA constructs were subcloned into Gateway entry
vectors and expression clones made as described
(Invitrogen). Below, the numbers given in parantheses in
the construct names refer to amino acid sequence
positions. All constructs were veriﬁed by DNA sequencing
(BigDye sequencing kit, Applied Biosystems).
The pSport1-SPBP plasmid encoding full-length human
SPBP was generated by inserting a 1.3kb KpnI fragment
of the 50RACE SPBP product (1) into the KpnI site
of pSport1-KIAA0292 (kindly provided by T. Nagase,
Kazusa DNA Research Institute). pcDNA3-HA-SPBP
was obtained by inserting a PCR product generated
from pSport1-SPBP using primers (50-CAGTCCTTTCG
GGAGCAAAGCAGTTAC-30 and 50-CTGGATCCT GT
GCTTGCTGTCCTTTCCATT-30) into the EcoRV site of
pcDNA3-HA. pGBKT7-SPBP(ePHD3-12) was generated
by inserting a PCR product obtained using the primers
(50-CTGGATCCTGTGCTTGCTGTCCTTTCCATT-30)
and (50-CTGGATCCTGTGCTTGCTGTCCTTTCCAT
T-30) into the NcoI site (blunted) of pGBKT7
(Clonetech). pENTR-SPBP was made by a two-step
cloning; ﬁrst a 4.6kb KpnI–XbaI fragment of pcDNA3-
HA-SPBP was inserted into the KpnI and XbaI sites of
pENTR1A (Invitrogen). Secondly, a PCR product
obtained using primers (50-CAGTCCTTTCGGGAGCA
AAGCAGTTAC-30 and 50-ACTACTCAACCCAGGAT
CTGTCAGTCG-30) and pSport1-SPBP as template
was digested with KpnI and DraI and inserted into
the same sites of the plasmid from step 1.pENTR-
SPBP(ePHD) was made using a PCR deletion strategy.
The pENTR-SPBP plasmid was ampliﬁed by PCR using
the primers (50-GCGGCGGCCGCCTAGACCCAGCTT
TCTTGTAC-30 and 50-GCGGCGGCCGCTCACTCTG
TCACAACAGGTCCCTGC-30) and cut with NotI and
DpnI before ligation using T4 DNA ligase (Invitrogen).
pENTR-SPBP (ePHD) was made by DraI and EcoRV
digestion of a PCR product obtained using primers (50-G
AAAGCAAGGCGCTCCCGGCC-30 and 50-CTGGAT
CCTGTGCTTGCTGTCCTTTCCATT-30) and insertion
into the DraI and EcoRV sites of pENTR1A.
pDONR207-SPBP(1333–1666) was made by BP recombi-
nation of the PCR product obtained using primers
(50-GGGGACAAGTTTGTACAAAAAAGCAGGCTG
CCCTGCTAAGACCAAAATACTGCC-30 and 50-GGG
GACCACTTTGTACAAGAAAGCTGGGTTGACCCT
TCCTGCCCCTCACTA-30) into the vector pDONR207
(Invitrogen).
The following TopBP1 constructs were made:
pENTR-TopBP1, encoding full-length TopBP1 was
made by inserting a 4.6kb EcoRI fragment from
pBluescript II SK
+-KIAA0259 (Kazusa DNA Research
Institute, T. Nagase) into the EcoRI site of pENTR1A.
pGST-TopBP1(862–1406) was generated by subcloning
a 1.7kb EcoRI–XhoI fragment from pGADGH-
TopBP1(862–1406) into the EcoRI and XhoI sites of
pGEX-4T-3 (Amersham Pharmacia Biotech). pENTR-
TopBP1(862–1011), encoding BRCT domain 6, was made
by inserting a 450bp EcoRI–SalI fragment from
pBluescript II SK+-KIAA0259 into the EcoRI and
XhoI sites of pENTR2B. A 1.6kb SalI–EcoRI fragment
from pBluescript II SK+-KIAA0259 encoding BRCT
domain 7 and 8, was ligated into the EcoRI and XhoI sites
of pENTR2B, generating pENTR-TopBP1(1012-1522).
pDestHA-TopBP1(BRCT6) was made by inserting a
blunt-ended 2.1kb SalI–EcoRI fragment from pENTR-
TopBP1 into pDestHA-TopBP1 cut with EcoNI (blunt-
ended) and EcoRV. The TopBP1(S1159A) and the
TopBP1(S1159D) mutants were generated by site-directed
mutagenesis using the Quick Change Site Directed
Mutagenesis Kit (Stratagene) and the sense primers
(50-GAGCAAGGCTTGCCGCCAATTTGC-30) for S1159A
and (50-GAGCAAGGCTTGCCGACAATTTGC-30) for
S1159D.
Three diﬀerent MMP3 reporter vectors were made
(i) pGL3-MMP3(2298), a 2298bp construct obtained by
PCR on genomic DNA using the primers (50-GACATG
TAGAATCTGCAAATCTAG-30 and 50-GAGTGACA
GTGTTTGTTTGGATCACC-30) and cloned into the
KpnI and BglII sites of pGL3Basic (Promega); (ii) pGL3-
MMP3, a 1448bp fragment obtained by SacI–BglII
digestion of the 2298bp MMP3 construct ligated into the
SacI–BglII sites of pGL3Basic, (iii) pGL3-MMP3-EtsMut,
obtained by mutating the two Ets1-binding sites in pGL3-
MMP3 to AATC and AGTT and changing the region
between them to TCGAGCCCGCTCGA.
pENTR-RAI1 was constructed using a three-step
strategy: First, the 2500 most 50-nucleotides were ampliﬁed
by PCR on human genomic DNA using primers (50-GCG
GGATCCGGATGCAGTCTTTTCGAGAAAGGTGT
GG-30 and 50-GCGGCGGCCGCGGAACAGCAGTGC
CGGCTGTCCTC-30) and inserted into the BamHI and
NotI sites of pENTR1A. The next 2300 nucleotides were
ampliﬁed by PCR on human genomic DNA using primers
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50-GGGTGGAGAAGCGAGACGCGTTCAC-30) and
inserted into the NotI and AgeI sites of the construct
from step 1. Finally, the C-terminal ePHD domain was
ampliﬁed by PCR using primers (50-GGGTGGAAAGCG
AGACGCGTTCAC-30 and 50-GCGGCGGCCGCCTAC
GGCAGCCTCTTATCTTTGGGAC-30) and IMAGE
clone 2231442 as template, and inserted into the NdeI
and NotI sites of the construct obtained in step 2. pENTR-
RAI1(ePHD) was ampliﬁed by PCR using primers (50-GC
AGCCGCGGCCTCCTTGCCC-30 and 50-CGAATTCC
GTTGGGGTGGATTACTACGGCAG-30) on human
pancreas Marathon Ready cDNA (Clonetech) and ligated
into DraI and EcoRI sites of pENTR1A. pDestTet-EGFP-
SPBP was constructed as follows: A puromycin resistance
casette was cloned into the XhoI site of pUH10-3 (22), and
the EGFP-tag (Eco47III–BamHI fragment of the pEGFP-
C1 plasmid (Clontech)) was cloned into the EcoRI–BamHI
sites. The Gateway reading frame cassette A was thereafter
cloned into the EcoRI site and full-length human SPBP
(2–1960) was recombined into the pDestTet-EGFP-
expression vector.
Yeast two-hybrid screen
The yeast two-hybrid screen was carried out with the
MATCHMAKER system (Clontech) according to the
manufacturer’s instructions, using the yeast strain PJ69-2a
expressing the ePHD(3–12) zinc-ﬁnger domain of SPBP as
bait [pGBKT7-SPBP(ePHD3–12)]. After mating with a
HeLa two-hybrid library (Clontech), 2 10
6 transfor-
mants were screened and selection was performed on yeast
minimal medium lacking Leu, Trp, His and Ade. Colonies
were picked 4 days after transformation and conﬁrmed by
b-galactosidase ﬁlter lift assays. Plasmids from positive
clones were puriﬁed and transformed into Escherichia coli
strain DH5a. The sequenced cDNA inserts were identiﬁed
by basic local alignment search tool (BLAST) searches of
the National Center for Biotechnology Information
(NCBI) database. In order to verify speciﬁc interactions
clones were re-screened as described previously (23).
Antibodies
The following primary antibodies were used: Rabbit
anti-SPBP antibody, raised against E. coli expressed
GST-SPBP(1016–1335), -(1108–1335) and -(1535–1597),
aﬃnity-puriﬁed using the antigen-mix coupled to KHL
(Biotrend Chemikalien GmbH, Koeln, Germany),
and diluted 1:500 for western blots, 20ml were used for
immunoprecipitations (IP) and 25ml for chromatin-
immunoprecipitations (ChIP); rabbit anti-TopBP1 anti-
body (ab2402, Abcam) diluted 1:1.000 for WB, 6mg for IP
and ChIP; mouse anti-TopBP1 antibody (cat. no.
611874, BD Bioscience Pharmingen) diluted 1:500 for
WB; rabbit anti-TopBP1 antibody (sc-32932, Santa Cruz
Biotechnology) diluted 1:200 for WB; rabbit anti-Ets1
antibody (ab11912, Abcam) 15mg for IP and ChIP; rabbit
anti-acetylated histone H3 antibody (Upstate) 10mg for
ChIP; rabbit anti-GFP antibody (ab290, Abcam) diluted
1:5.000 for WB, 2ml for IP; mouse anti-HA antibody
(clone12CA5, Roche) diluted 1:1.000 for WB, 0.1mg for
IP; rabbit anti-MMP3 antibody (ab28948, Abcam) diluted
1:5.000 for WB; rabbit anti-b-actin antibody (Sigma)
diluted 1:1.000 for WB.
Secondary antibodies used were: HRP-conjugated goat
anti-rabbit IgG and anti-mouse IgG antibodies
(BD Bioscience Pharmigen) diluted 1:2.000 for WB;
HRP-conjugated goat anti-rabbit IgG and anti-mouse
IgG antibodies (Pierce) diluted 1:5.000 for WB.
Cellculture
HeLa cells (ATCC CCL2) and IMR90 cells (ATCC CCL
186) were grown in Eagle’s minimum essential medium
(MEM) supplemented with 10% fetal bovine serum (FBS),
penicillin (100U/ml), and streptomycin (100mg/ml)
(Invitrogen). All experiments using IMR90 cells were
carried out between passages 12 and 18. For induction of
MMP3, 4 10
4 cells/well were seeded in 24-well dishes
2daysbefore transfection. The cellswere starvedfor24hin
MEM with 0.1% FBS before being transfected twice with
50nM SPBP siRNA or 50nM scrambled siRNA
(Dharmacon) using Lipofectamine 2000 (Invitrogen). The
cells were starved in MEM without serum 24h post-
transfection. The medium was then replaced with 200ml
fresh MEM supplemented with 1ng/ml Phorbol
12-myristate 13-acetate (PMA) (P1585, Sigma) followed
by 20h incubation after which 21ml of the medium was
harvested for western blotting. U2OS-TA cells, a kind gift
from Dr Jiri Lukas, Danish Cancer Society, Denmark,
were maintained in Dulbecco’s modiﬁed Eagle’s medium
(DMEM) supplemented with 10% FBS and the antibiotics
described above. In addition, 400mg/ml geneticin, (G418,
Sigma) was added to the medium. The Tet-oﬀ gene
expression system (22), was used for the regulated
expression of GFP-SPBP in U2OS-TA cells, a human
osteosarcoma cell line with stably integrated tetracycline-
regulated transcriptional activator (tet-VP16) and a neo-
mycin resistance gene (24). Following transfection of these
cells with pDestTet–GFP–SPBP stably transfected clones
were selected in medium containing puromycin dihy-
drochloride (1mg/ml). Single colonies were picked and the
expression of GFP-tagged SPBP was veriﬁed using
ﬂuorescence microscopy and western blotting. For repres-
sion of the transgene, cell monolayers were washed three
times with PBS, trypsinated and plated into media with
2mg/ml doxycycline.
GST pull-down assays
Expression of GST-fusion proteins (1) and GST-
pull-down assays (25) were as described previously. For
expression of GST fusion proteins containing the ePHD
domain of SPBP, 0.1mM ZnCl2 was added to the growth
medium. When benzonase was used 0.5ml of 520U/ml
benzonase was added to the binding reactions followed
by incubation for 10min at room temperature before
incubation at 48C for 1h.
IP andimmunoblotting
In vitro co-IP assays were described previously (23). Co-IP
of over-expressed and endogenous proteins were
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6 U2OS cells per antibody
were harvested in 1ml lysis buﬀer (20mM Tris–HCl,
pH 8.0, 150mM NaCl, 1mM EDTA, 0.5% NP-40) (13)
supplemented with protease inhibitor cocktail (Roche),
phosphatase inhibitor cocktail (Calbiochem) and soni-
cated brieﬂy. The cell lysates were pre-cleared by incu-
bation with 20ml Protein-A Sepharose beads (Amersham)
for 30min, 48C on a rotating wheel. The pre-cleared cell-
lysates were incubated with the appropriate antibody
overnight at 48C on a rotating wheel. BSA-saturated
Protein-A Sepharose beads (30ml) were added and the
incubation continued for 1h. The beads were washed
3 1ml in lysis buﬀer, re-suspended in 20ml2  SDS
loading buﬀer and resolved on SDS–PAGE gels.
Co-precipitated proteins were detected by western blot-
ting. Biotinylated Protein Ladder (Cell Signaling) was run
in parallel for determination of MW. Detection was
performed using ECL- (Santa Cruz Biotechnology) or
ECL SuperSignal Femto Molar Detection kits (Pierce)
and a LumiAnalyst imager (Roche Applied Sciences).
Reporter geneassays
HeLa cells were seeded at a density of 10
5 cells/well in
six-well plates and transfected 24h later using the calcium
phosphate co-precipitation method. Transfections were
performed with 1mg of various SPBP and TopBP1
expression plasmids together with 0.1mg of pRc-Ets68
(26) or 0.5mg pCMV-Tag2a-Ets-1 (27). The empty
expression vector pcDNA3-HA (23) was used as control.
The plasmids p1p2mycluc (28) (0.5mg) or pGL3-MMP3
(0.5mg) were used as reporters, and the b-galactosidase
expressing pCMV-b-gal vector (0.1mg) (Stratagene) was
included to determine transfection eﬀeciency. Cells were
harvested 24h post-transfection and luciferase activities
measured using the Dual Light luciferase and
b-galactosidase kit (TROPIX) on a Luminoskan RT
dual injection luminometer (Labsystems). All reporter
gene assays were carried out in three parallel experiments
and repeated several times. The luciferase values varied
1–12% between the parallels.
Reporter gene assays involving siRNA-mediated
knock down of SPBP or TopBP1 were performed as
follows: HeLa cells seeded in 24-well dishes at 2 10
5
cells/well the day before transfection were transfected
using Lipofectamine PLUS (Invitrogen) with reporter
vectors (30ng), expression vectors pRc-Ets68 (15ng) and
pcDNA3-HA-TopBP1 (60ng) and 50nM of SPBP siRNA
oligos (siGENOME SMARTpool TCF20 siRNAs,
Dharmacon), 50nM of Scrambled siRNA oligos
(Dharmacon) or 50nM of TopBP1 siRNA oligos [synthe-
sized by Ambion, sequence as described in (15)]. pCMV-
b-gal (10ng) was included to determine transfection
eﬃciency. The cells were harvested 2 days post-
transfection and the luciferase and b–galactosidase
activities determined.
ChIP
ChIP was performed mainly as described in the
Chromatin Immunoprecipitation Assay Kit (Upstate
catalog no. 17–295). 1.5 10
7 U2OS–GFP–SPBP cells
were used for each tested condition. Crosslinking with
1% formaldehyde was performed for 10min. at room
temperature. This was stopped by adding 0.125M glycine
for 5min. Harvested cells were re-suspended in 500ml lysis
buﬀer (1% SDS, 10mM EDTA, 50mM Tris–HCl pH 8.1,
protease inhibitor cocktail), and incubated 10min on ice
before sonication for 15min in a Bioruptor (Diagenode).
The DNA fragments were puriﬁed using a QIAquick
Spin Kit (QIAGEN). One to 5mlo fa3 0 ml DNA
puriﬁcation was used for 30–35 cycles of PCR ampliﬁca-
tion. PCR primers used to amplify the c-myc P2 promoter
were (50-TCGGGGCTTTATCTAACTCG-30) and (50-GC
TGCTATGGGCAAAGTTTC-30), while the MMP3 pri-
mers used were (50-TCCAGTTTTCTCCTCTA CCAAGA
C-30) and (50-TTGCTTTCATCCAAATGGCAGCAG30).
Primers for the control PCRs were: cathepsin D control
(50-TCTGGCCCCACTGGCCATCCGCAC-30) and (50-C
TTTCCAGTGGGCTGGGATCTTGG-30), MMP3 con-
trol (50-CAGGTGTGCACTGCCACAAGTGGC-30) and
(50-AACCTAGCCAAGGAAAGAATCCC-30), c-myc
control (50-GAGTTTGAGACCAGCCTGGGCAAC)
and (50-CCTGGACTCAGGTGATCCTCCTAC-30).
RESULTS
SPBP and TopBP1 interact in vitrovia theePHD
and BRCT6 domains
The ePHD domain (amino acids 1690–1960) of SPBP can
be viewed as composed of a ‘core PHD domain’ with eight
zinc ligands (ePHD5–12) with four additional ligands
N-terminal to the core making up a third ﬁnger. A yeast
two-hybrid screen using the C-terminal ePHD3-12 region
of SPBP (amino acid 1837–1960) as bait (Figure 1A),
identiﬁed the DNA damage checkpoint mediator TopBP1
as a putative interaction partner. We denote the bait
fragment ePHD3-12 since it contains the 10C-terminal
zinc ligands (3–12). This region has previously been called
the ZNF2 domain and is conserved between SPBP and
members of the trithorax family proteins such as MLL,
MLL2 and  4 (1). Nearly 60% (165 of 280) of the positive
clones sequenced encoded BRCT domains 6 and 7 and
part of BRCT domain 8 of TopBP1 [TopBP1(862–1406)]
(Figure 1A). Co-immunoprecipitation assays of in vitro
translated HA-tagged TopBP1 (HA-TopBP1) and
Myc-tagged SPBP (Myc-SPBP) demonstrated interaction
between the full-length proteins in vitro (Figure 1B).
To verify the interaction in vitro and to determine
whether the complete ePHD domain of SPBP also could
interact with TopBP1, GST pull-down assays using
GST-fusions of SPBP(ePHD3-12) and SPBP(ePHD),
and in-vitro translated HA-tagged TopBP1(862–1406)
were performed. As shown in Figure 1C, TopBP1
(862–1406) binds to both SPBP(ePHD) and
SPBP(ePHD3-12) with the strongest interaction observed
with SPBP(ePHD3-12).
To map the domain of TopBP1 responsible for the
interaction with full-length SPBP, two deletion mutants
of TopBP1 were constructed. A region containing the
BRCT6 domain of TopBP1 (amino acids 862–1011) and
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1012–1522) (Figure 1A) were produced as GST fusion
proteins and tested for interaction with in vitro translated
HA-tagged SPBP (HA-SPBP). As seen in Figure 1D,
full-length SPBP bound to BRCT domain 6 of TopBP1.
Since the BRCT domains of TopBP1 are shown to bind
double- and single-stranded DNA (29), we wanted to test
whether the interaction between SPBP and TopBP1 is
indirect via DNA. Complete removal of DNA by
treatment with the nuclease benzonase had no eﬀect on
the interaction between SPBP and TopBP1(862–1406).
Clearly, DNA is not a ‘bridging factor’ between the two
proteins (Figure 1D).
Next, the interaction between TopBP1 and a deletion
mutant of SPBP lacking the ePHD domain was
investigated. Surprisingly, SPBP(ePHD) bound both to
TopBP1(BRCT6) (Figure 1E) and TopBP1(BRCT7+8)
(data not shown), even though the interaction was
clearly weaker than for the full-length SPBP (Figure 1E).
To further delineate which region of SPBP that was
involved in this additional interaction, three deletion
constructs of SPBP (amino acids 4–486,  532–1344 and
 1333–1666) were in vitro translated and assayed by
GST-pulldown with GST-TopBP1(BRCT6) and GST-
TopBP1(BRCT 7+8). These studies showed that the
SPBP region containing amino acids 1333–1666 interacted
weakly both with BRCT6 (Figure 1F) and BRCT7+8
of TopBP1 (data not shown). This region of SPBP
encompasses the DNA-binding domain and a bipartite
nuclear localization signal (1) (Figure 1A). In conclusion,
SPBP and TopBP1 interact in vitro primarily via the ePHD
domain of SPBP and the BRCT6 domain of TopBP1. This
interaction is not dependent on DNA. There are also
weaker contributing interactions involving amino acids
1333–1666 of SPBP and BRCT7+8 domains of TopBP1.
SPBP and TopBP1 interact in vivo
To investigate the SPBP–TopBP1 interaction in vivo
we ﬁrst established a U2OS-TA cell line stably
expressing GFP-SPBP (U2OS-GFP-SPBP) as described
in Materials and Methods section. U2OS-TA is a human
osteosarcoma cell line with a stably integrated tetracycline
regulated transcriptional activator (tet-VP16) (24).
This system allows regulated expression of the transgene
in a doxycycline-repressible manner. A clone expressing
GFP-SPBP at the level of endogenous SPBP that
displayed eﬃcient doxycycline-mediated repression of
GFP-SPBP expression was used for the further study
(Figure 2A). HA-tagged TopBP1 was transiently
expressed in the U2OS-GFP-SPBP cell line, and an anti-
GFP antibody was used to immunoprecipitate GFP-SPBP
from total cellular extracts. As shown in Figure 2B,
HA-TopBP1 was co-precipitated with GFP-SPBP. Next,
we wanted to determine whether endogenous TopBP1 was
co-precipitated with SPBP. SPBP was immunoprecipitated
from total U2OS-GFP-SPBP cellular extracts with anti-
SPBP antibodies, and the associated TopBP1 was detected
by anti-TopBP1 antibodies on a western blot. Figure 2C
shows that endogenous TopBP1 was co-precipitated with
SPBP. The weak band of co-precipitated TopBP1 may
reﬂect the expression level of TopBP1 in an extract from
unsynchronised cells. TopBP1 generally displays a low
expression level, except during S-phase when its expres-
sion is induced (19,30). Similarly, IP of endogenous
TopBP1 using TopBP1 antibodies showed that both
endogenous SPBP and the fusion protein GFP-SPBP
were associated with TopBP1 (Figure 2D). Although the
co-immunoprecipitations of endogenous proteins dis-
played some background with pre-immune serum, the
SPBP and TopBP1 signals were reproducibly above
background in several independent experiments.
Figure 2. SPBP and TopBP1 interact in vivo.( A) Expression of GFP-
SPBP stably integrated into the genome of the U2OS-TA cell line.
Growing the cells in the presence of doxycycline represses the expression
of the integrated GFP-SPBP (left lane). Removal of doxycycline induces
expression of GFP-SPBP at a similar level as the endogenous protein
(middle lane). Total cellular extracts from U2OS-TA cells containing the
GFP-SPBP minigene grown in the presence or absence of doxycycline
were separated by SDS–PAGE (5%) and immunoblotted using an anti-
SPBP antibody. (B) GFP-SPBP and HA-TopBP1 interact in U2OS-GFP-
SPBP cells. U2OS-GFP-SPBP cells were transfected with a HA-TopBP1
expressing plasmid. One day after transfection immunoprecipitations
wereperformedusingananti-GFP antibody.The co-precipitatedproteins
were detected by western blotting using an anti-TopBP1 antibody (upper
panel). Immunoprecipitated SPBP was visualized using the anti-GFP
antibody (lower panel). (C) SPBP co-precipitate endogenous TopBP1.
Immunoprecipitations from U2OS-GFP-SPBP cells were performed
using an anti-SPBP antibody. The co-precipitated proteins were detected
by western blotting using an anti-TopBP1 antibody (upper panel).
Immunoprecipitated SPBP was visualized using an anti-SPBP antibody
(lower panel). The two SPBP bands correspond to GFP-SPBP (upper
band) and endogenous SPBP (lower band). (D) Endogenous TopBP1
co-precipitate SPBP. Immunoprecipitations were performed using an
anti-TopBP1 antibody. The co-precipitated proteins were detected by
western blotting using an anti-SPBP antibody (upper panel).
Immunoprecipitated TopBP1 was visualized using the anti-TopBP1
antibody (lower panel). The two SPBP bands correspond to GFP-SPBP
(upper band) and endogenous SPBP (lower band).
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transcriptional activation
TopBP1 is a checkpoint control protein shown to
re-localize to DNA repair foci containing ATR and
BRCA1 upon induction of double-strand breaks (20,30).
However, in contrast to TopBP1, SPBP did not re-localize
to foci or stripes of DNA double-strand breaks induced
by X-ray irradiation (10Gy) or local laser micro-
irradiation of HeLa or HT1080 cells (data not shown).
Furthermore, the protein level of SPBP did not change
upon DNA damage or during S-phase as is the case for
TopBP1 (data not shown). We therefore chose to focus
our study on the interplay between SPBP and TopBP1 in
regulation of gene expression. SPBP has been shown to
enhance the transcriptional activity mediated by Ets1 on
the c-myc P1P2 promoter (1). Hence, we decided to
investigate whether TopBP1 would modulate the positive
eﬀect of SPBP on Ets1-mediated transcriptional activa-
tion. Transient co-transfection studies in HeLa cells using
a luciferase reporter vector containing the c-myc P1P2
promoter (28) and the p68 chicken form of Ets1 (Ets68)
were performed. As seen in Figure 3A, TopBP1 stimulates
Ets68-mediated transcriptional activation of the c-myc
P1P2 promoter, but to a lesser extent than SPBP.
However, a more than additive activation of the P1P2
promoter was observed when both SPBP and TopBP1
were co-expressed with Ets68.
The occupancy of SPBP and TopBP1 on the c-myc
P2 promoter was examined by ChIP assays using the
U2OS-GFP-SPBP cells. As shown in Figure 3B, c-myc P2
promoter sequences were detected in both SPBP- and
TopBP1 immunoprecipitates strongly suggesting that both
SPBP and TopBP1 are located on the c-myc P2 promoter.
IP of acetylated histone H3 was used as a positive control
conﬁrming that the endogenous c-myc P2 promoter was
transcriptionally active. As a control, PCR analyses did
not detect any binding of SPBP- or TopBP1 to a region
 4100bp upstream the c-myc P2 promoter. We also
included a region around 3kb upstream of the cathepsin
D gene promoter as an additional negative control
(Figure 3B; lower panels).
Ets1 was recently shown to be a main activator of the
MMP3 (Stromelysin-1) promoter via binding to tandem
Ets1-binding sites (EBS) at position  216 and  201
(Figure 4A) (31). To test whether the stimulation of Ets1-
mediated transactivation by SPBP and TopBP1 observed
with the c-myc promoter could be a more general
phenomenon, similar co-transfection experiments were
performed using the MMP3 promoter. As seen in
Figure 4B, SPBP and TopBP1 co-operated to enhance
Ets68-mediated activation of the MMP3 promoter.
Similar results were obtained when the p54 form of
murine Ets1 (27) was co-expressed instead of the chicken
p68 Ets1 (Figure 4C). To conﬁrm that the MMP3
promoter-region harbouring the EBS could be occupied
by SPBP and TopBP1 in addition to Ets1 itself we
performed ChIP assays using the U2OS–GFP–SPBP cells.
As shown in Figure 4D, in addition to Ets1, both SPBP
and TopBP1 bind to the MMP3 promoter. The speciﬁc
binding of these proteins to the MMP3 promoter
Figure 3. SPBP and TopBP1 associate with the c-myc promoter
and co-operate to enhance Ets1-mediated transcriptional activation
of this promoter. (A) When SPBP and TopBP1 are co-expressed
with Ets68, a more than additive activation of Ets68-mediated
transcription of the c-myc P1P2 promoter is observed. Transient
transfection assays were carried out in HeLa cells using 0.5mgo f
the reporter p1p2mycluc, together with expression vectors for
Ets68 (0.1mg), HA-SPBP (1.0mg) and/or HA-TopBP1 (1.0mg) as
indicated. The data represent the mean of three independent
experiments, each performed in triplicate. (B) Chromatin immuno-
precipitation assays show that both SPBP and TopBP1 associate
with the c-myc promoter. Extracts from U2OS-GFP-SPBP cells
(1.5 10
7 cells per antibody) were immunoprecipitated with
preimmune serum (IgG), polyclonal anti-SPBP antibody, polyclonal
anti-TopBP1 antibody and anti-acetylated histone H3 antibody
(positive control). Input control (1:50) was included (lane 7). PCR
analyses on the immunoprecipitated chromatin were carried out
using primers ﬂanking the c-myc P2 promoter (position  28 and
+200 respectively), primers aligning to positions  4107 and  3949 of
the c-myc P2 promoter (c-myc P2 Promoter Control), and primers
aligning to positions  3351 and  3069 of the cathepsin D promoter
(cathepsin D Promoter Control). The 1kb DNA ladder is shown
to the left.
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upstream the MMP3 promoter. No binding was detected
to that region. We also included a region around 3kb
upstream the cathepsin D gene promoter as an additional
negative control (Figure 4D, lower panels). To further test
the role of SPBP in Ets1-mediated transcriptional activa-
tion of the MMP3 promoter, endogenous SPBP was
depleted by transfecting HeLa cells with SPBP siRNAs.
Of four diﬀerent siRNAs tested, all caused a signiﬁcant
knockdown of SPBP (Figure 4E). Reporter gene assays
performed upon knockdown of SPBP using siRNA oligo 2
(Figure 4F) or  1 (data not shown) showed a small but
signiﬁcant reduction of the transcriptional activation
potential of over-expressed Ets1 on the MMP3 promoter
(Figure 4F). Importantly, the co-activation potential of
TopBP1 was completely lost when SPBP was knocked
down (Figure 4F). Similar results were obtained using the
c-myc P1P2 promoter (data not shown). These results
indicate that SPBP acts as a co-activator of Ets1, and that
the TopBP1-mediated enhancement of Ets1 activity is
strongly dependent on SPBP.
Next, we addressed the role of TopBP1 in Ets1-
mediated transcriptional activation of the MMP3 and
the c-myc P1P2 promoters. Endogenous TopBP1 expres-
sion was knocked down using a previously published
TopBP1 siRNA (15) (Figure 4G). A small but reprodu-
cible reduction in Ets1 transcriptional activity was seen
when TopBP1 was knocked down while the co-activation
potential of SPBP was strongly reduced (Figure 4H).
Similar results were obtained using the c-myc P1P2
promoter (data not shown). Thus, these data suggest
that TopBP1 may act as a co-activator of Ets1, and that
the co-activation potential of SPBP is signiﬁcantly
enhanced by the presence of TopBP1.
To conﬁrm that the induction of the MMP3 promoter
was via Ets1, the tandem EBS in the MMP3 promoter
(Figure 4A) were mutated and the mutant promoter tested
in reporter gene assays. As shown in Figure 5, mutation of
the tandem EBS abolished both Ets1 activation of the
MMP3 promoter and the stimulatory eﬀect of SPBP or
TopBP1 on this promoter. When all three proteins were
co-expressed, the mutated promoter was induced but
to a much lower extent than the wild-type promoter.
This residual induction is very likely due to activation
via weaker Ets1 responsive sites at position  92/ 73,
 344/ 355 and  72/ 48 (32). Hence, the SPBP- and
TopBP1-mediated stimulatory eﬀect on the MMP3
promoter is mainly dependent on Ets1 binding to the
tandem EBS.
Lowering the level ofSPBP reduces phorbol ester induced
MMP3 secretion in IMR90 fibroblasts
Recently it was reported that down-regulation of Ets1 in
HIG-82 cells reduced the phorbol ester-induced expression
from the MMP3 promoter (31). To further characterize
the eﬀect of SPBP on Ets1-mediated stimulation of the
MMP3 promoter, we determined the impact of SPBP
down-regulation on phorbol ester-induced MMP3 secre-
tion in the human ﬁbroblast cell line IMR90. The IMR90
cells were transfected with SPBP siRNA or control
siRNA, serum starved and stimulated with phorbol ester
before performing western blot on the cell medium to
determine the level of secreted MMP3 (Figure 6A). The
level of secreted MMP3 was normalized to the level of
actin of harvested cells (Figure 6B). Eﬀective knockdown
of SPBP was monitored by immunoblotting (insert in
Figure 6B). Strikingly, siRNA-mediated knockdown of
SPBP lead to a 50% reduction in the level of secreted
MMP3. These results clearly demonstrate the importance
of endogenous SPBP for Ets1-mediated activation of
MMP3 expression in IMR90 cells.
The relatedePHD domain-containing proteinRAI1does
notenhance Ets1 transcription orinteract withTopBP1
RAI1 (retinoic acid-induced 1) is a nuclear retinoic acid-
induced protein containing seven short regions with strong
homology to SPBP (denoted A–F in Figure 1A) (1,33,34).
Importantly, RAI1 also possesses a C-terminal ePHD
domain, an N-terminal transactivation domain and three
nuclear localisation signals (35,36). The gene organization
of SPBP and RAI1 is remarkably similar suggesting that
they represent duplicated genes with a common ancestor
(36). RAI1 is implicated in Smith–Magenis syndrome,
a syndrome with multiple congenital anomalies and mild
mental retardation (35,36). The ePHD domain of RAI1 is
organized similarly to the SPBP ePHD domain with an
extended loop region between the two most N-terminal
zinc-ligands and the conserved region containing the PHD
ﬁngers. We decided to test whether RAI1 had the ability
to enhance Ets1-mediated transactivation of the MMP3
promoter similar to SPBP. However, comparative reporter
gene assays in HeLa cells showed that RAI1 neither
stimulated Ets1-mediated transcriptional activation of the
MMP3 promoter nor co-operated with TopBP1
(Figure 7A and B). On the contrary, RAI1 repressed
Ets1-mediated transcriptional activation. Next, we asked
whether the ePHD domain of RAI1 had the ability to
interact with TopBP1. Interestingly, a yeast two-hybrid
assay revealed that RAI1 has very low aﬃnity for TopBP1
compared to the SPBP ePHD domain (Figure 7D). This
was conﬁrmed by GST pull-down assays (data not
shown). In contrast to RAI1, the ePHD domains from
the trithorax group proteins MLL, MLL2 and -4 can bind
to TopBP1 suggesting that this is a more general feature of
some ePHD domains. However, the RING ﬁnger protein
hRNF4, known to interact with SPBP and carrying a zinc-
ﬁnger domain related to the ePHD domain (3), does not
bind to TopBP1 (Figure 7D).
The ePHD domain ofSPBP and theBRCT6 domain of
TopBP1 arerequired fortheir ability to co-operate in
stimulating Ets1-mediated transcription
As described above the interaction between SPBP and
TopBP1 is mainly mediated by the ePHD domain of SPBP
and the BRCT6 domain of TopBP1. To determine the
importance of these regions for their ability to co-activate
Ets1-mediated transcription, a C-terminal deletion mutant
of SPBP lacking the ePHD domain, SPBP(ePHD), and a
TopBP1 deletion mutant lacking BRCT6,
TopBP1(BRCT6), were tested in reporter gene assays
Nucleic Acids Research, 2007, Vol. 35, No. 19 6655Figure 4. SPBP and TopBP1 co-operate to enhance Ets1-mediated transcriptional activation of the MMP3 promoter. (A) Schematic representation
of the human MMP3 promoter. Arrowheads indicate the position of forward and reverse primers ( 231 and  65, respectively) used for ChIP. EBS:
Ets1-binding sites, NIP/UEF3: nuclear inhibitory protein/urokinase-type plasminogen activator enhancer factor 3, SPRE: Stromelysin-1 PDGF-
responsive element. (B) SPBP and TopBP1 co-operate to enhance Ets68-mediated activation of the MMP3 promoter. Transient transfections were
carried out in HeLa cells as described in Figure 3A except that the reporter plasmid contains 1448bp of the human MMP3 promoter in front of the
luciferase gene. The data represent the mean of four independent experiments, each performed in triplicate. (C) SPBP and TopBP1 co-operate
to enhance Ets54-mediated transcriptional activation of the MMP3 promoter. Transient transfections were carried out in HeLa cells as described in
(B) except that an expression vector for murine Ets54 (27) was used instead of the Ets68 expression vector. The data represent the mean of
6656 Nucleic Acids Research, 2007, Vol. 35, No. 19using the MMP3 promoter as read-out. Figure 8A shows
that both SPBP(ePHD) and TopBP1(BRCT6)
enhanced Ets1-mediated transcriptional activity similar
to the full-length proteins. However, SPBP(ePHD)
co-operated less eﬃciently with TopBP1 than full-length
SPBP did. Likewise, TopBP1(BRCT6) co-operated less
eﬃciently with SPBP than full-length TopBP1 did. Also,
when deletion mutants of both SPBP and TopBP1 are
over-expressed together with Ets1, co-operation between
TopBP1 and SPBP is completely abolished, leaving only
the additive eﬀect. Western blots and immunostaining
showed that the deletion mutants are expressed at similar
levels as the full-length proteins (Figure 8B) and are
present in the cell-nucleus (data not shown). These results
indicate that the co-operation between SPBP and TopBP1
is dependent on interactions involving the ePHD domain
of SPBP and the BRCT6 domain of TopBP1. The weak
co-operation displayed when only the ePHD domain or
only the BRCT6 domain was deleted may either be due to
(i) the region encompassing amino acids 1333–1666 of
SPBP and BRCT7+8 of TopBP1 or (ii) the fact that both
TopBP1(20) and SPBP(data not shown) have the ability to
oligomerize. Hence, the weak eﬀect may be caused by
endogenous proteins recruited to the promoters by
interaction with the deletion mutants.
Phosphorylation-induced oligomerization of TopBP1 is
required forco-operation withSPBP
Recently it was reported that serine 1159 of TopBP1 is
an Akt/PKB substrate (20). Phosphorylation of S1159
induces oligomerization of TopBP1, and this oligomeriza-
tion is speciﬁcally required for its interaction with the
transcription factors E2F1, Miz-1 and HPV E2. Liu et al.
(20) suggested that TopBP1 oligomerization could be
a general requirement for its involvement in transcrip-
tional regulation. To test whether TopBP1 oligomeriza-
tion is required for co-operation with SPBP to enhance
Ets1 activity, serine 1159 of TopBP1 was mutated to
alanine and co-expressed with Ets1 or Ets1 and SPBP in
HeLa cells. Reporter gene assays using the MMP3
promoter revealed that TopBP1(S1159A) had a reduced
ability to enhance Ets1-mediated transcriptional activity
and to co-operate with SPBP (Figure 8C). To further
verify that this S1159 phosphorylation site is important
phosphorylation at this site was mimicked by expressing
a TopBP1(S1159D) mutant. TopBP1(S1159D) displayed
an even stronger enhancement of Ets1 activation
together with SPBP than wild-type TopBP1 (Figure 8C).
These results strongly suggest that co-operation
between SPBP and TopBP1 to stimulate Ets1-mediated
transactivation is dependent on phosphorylation-induced
oligomerization of TopBP1.
DISCUSSION
In this study, we present evidence for physical and
functional interactions between SPBP and TopBP1. The
physical interaction is mainly mediated by the ePHD
domain of SPBP and the BRCT6 domain of TopBP1.
There is also a weaker interaction between BRCT6 of
TopBP1 and a region encompassing amino acids
1333–1666 of SPBP. Similarly, the BRCT domains 7
and -8 of TopBP1 could also interact weakly with the
ePHD of SPBP. Upon induction of DNA double-strand
breaks, TopBP1 is recruited to sites of damage where it
plays an important role as an adaptor protein to facilitate
phosphorylation of Chk1 by the ATR kinase (11,37).
However, in contrast to TopBP1, SPBP is not recruited to
sites of DNA double-strand breaks (data not shown).
Hence, we have so far no evidence for a role of SPBP
in DNA damage responses, but this issue deserves further
investigation. Here we decided to focus on functional
studies of the SPBP-TopBP1 interaction in gene regula-
tion since both SPBP and TopBP1 are implicated in
transcriptional regulation (1,17,18,20,21,38). Reporter
gene assays using two diﬀerent Ets1-regulated promoters
demonstrated that TopBP1 and SPBP co-operate to
enhance Ets1-mediated transcriptional activation. This
co-operation was dependent on their interaction domains
(the ePHD domain of SPBP and the BRCT6 domain of
TopBP1) in addition to phosphorylation of serine 1159 of
TopBP1 (20). ChIP showed that both TopBP1 and SPBP
are associated with these Ets1-regulated promoters, and
siRNA-mediated knockdown of SPBP in a ﬁbroblast cell-
line revealed that the endogenous levels of SPBP aﬀected
the expression of the Ets1-regulated matrix metallopro-
teinase MMP3. Mutation of the tandem EBS in the
MMP3 promoter demonstrated that the stimulatory eﬀect
two independent experiments, each performed in triplicate. (D) Chromatin immunoprecipitation assays show that Ets1, SPBP and TopBP1 are associated
with the MMP3 promoter. Extracts from U2OS-GFP-SPBP cells (1.5 10
7 cells per antibody) were immunoprecipitated with preimmune serum (IgG),
polyclonal anti-Ets1 antibody, polyclonal anti-SPBP antibody and polyclonal anti-TopBP1 antibody. Input control (1:50) was included (lane 2). PCR
analyses on the immunoprecipitated chromatin were carried out using primers aligning at position  231 and  65 of the MMP3 promoter. Control PCR
analysis was carried out using primers aligning to positions  3537 and  3326 of the MMP3 promoter, and positions  3351 and  3069 of the cathepsin D
promoter. The 1kb DNA ladder is shown to the left. (E) Western blot showing knockdown of SPBP in HeLa cells using four diﬀerent siRNA oligos.
Transient transfections were carried out using siRNA oligos 1–4 alone and mixed (50nM) as indicated. Cell lysates were separated by SDS–PAGE (6%),
and immunoblotted using the anti-SPBP antibody (upper panel). The blots were re-probed with ananti-b-actin antibody in order to determine the amount
of loaded protein (lower panel). (F) Down-regulation of SPBP using siRNA decreased the transcriptional activation of MMP3 promoter mediated by
either Ets1 alone or Ets1 and TopBP1 together. Transient transfections were carried out in HeLa cells using the pGL3-MMP3 reporter plasmid (30ng),
together with the expression plasmids for Ets68 (10ng) and HA-TopBP1 (50ng), and a SPBP-speciﬁc siRNA (50nM) or scrambled siRNA as indicated.
Cells were harvested 40h post-transfection. The data represent the mean of three independent experiments performed in triplicate. (G) Western blot
showing siRNA-mediated knockdown of TopBP1 in HeLa cells. Transient transfections were carried out using 50nM TopBP1 siRNA or 50nM Control
siRNA. Cell lysates were separated by SDS–PAGE (6%), and immunoblotted using an anti-TopBP1 antibody (upper panel). b-actin was used as loading
control (lower panel). (H) Down-regulation of TopBP1 using siRNA decreased the transcriptional activation of the MMP3 promoter mediated by either
Ets1 alone or Ets1 and SPBP together. Transient transfections were carried out as described in (F) except that an expression plasmid for SPBP was used
instead of the TopBP1 expression plasmid, and TopBP1 speciﬁc siRNA was used instead of the SPBP siRNA. The data represent the mean of two
independent experiments performed in triplicate.
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sites.
The interaction between SPBP and TopBP1 shows
similarity to the E2F1–TopBP1 interaction (20). The
interaction is dependent on the BRCT6 domain of
TopBP1 and on oligomerization of TopBP1 induced by
phosphorylation on serine 1159 (20). Liu et al. (20)
suggested that oligomerization of TopBP1 was speciﬁcally
required for TopBP1 to interact with transcription factors.
Our results are in line with this hypothesis. BRCT
domains have been identiﬁed as phosphopeptide-binding
modules (39–41). BRCT domain 6 of TopBP1 binds
preferentially to an E2F1 peptide phosphorylated at a
serine residue, rather than the unphosphorylated counter-
part (41). The ePHD domain of SPBP has several
potential serine-, threonine- and tyrosine phosphorylation
sites as predicted by the NetPhos 2.0-(42) and ScanSite
(43) servers. However, phosphorylation of the ePHD
domain of SPBP is not essential for binding to TopBP1
since an E. coli-produced GST fusion of the ePHD
domain is capable of interacting with in vitro-translated
TopBP1.
TopBP1 is reported to act both as a repressor and as an
activator of transcriptional activity (16–18,21). Here we
present evidence that TopBP1 has a stimulatory eﬀect on
Ets1 transcriptional activity of the c-myc P1P2 promoter
and the MMP3 promoter. Co-overexpression of TopBP1
and SPBP resulted in a more than additive enhancement
of transcriptional activation mediated by Ets1 on both
these promoters. Interestingly, preliminary results suggest
that SPBP and TopBP1 can also co-operate to stimulate
c-Jun transcriptional activity (data not shown). Thus,
their co-operation in activating transcription is most likely
not limited to Ets1. The stimulatory eﬀect of SPBP and
TopBP1 is signiﬁcantly reduced when the level of
endogenous SPBP or endogenous TopBP1 is knocked
down by speciﬁc siRNAs. SPBP is reported to bind to the
SPRE-element at position  1578 of the MMP3 promoter
and stimulate its transcriptional activity (Figure 4A) (2).
Figure 5. The stimulation of Ets1 activation of the MMP3 promoter by
SPBP and TopBP1 is dependent on the tandem Ets1-binding sites.
Transient transfections were carried out in HeLa cells as described in
Figure 3A except that two diﬀerent luciferase reporter gene plasmids
were used, one containing the wild-type human MMP3 promoter
(1448bp upstream sequence), and one containing the human MMP3
promoter with the tandem Ets1-binding sites mutated. The data
represent the mean of two independent experiments, each performed
in triplicate. Figure 6. The level of endogenous SPBP aﬀects the level of phorbol
ester-induced MMP3 secretion. (A) A western blot showing the eﬀect of
down-regulation of endogenous SPBP on the level of secreted MMP3
induced by PMA in IMR90 ﬁbroblasts. Cells were starved in MEM
with 0.1% FBS for 24h before being transfected two following days
with SPBP siRNA (50nM) or scrambled siRNA (50nM). The cells
were starved in MEM without serum for 24h post-transfection before
stimulation with MEM containing 1ng/ml PMA for 20h. Medium
samples were analysed by SDS–PAGE (7.5%) and immunoblotting
with an MMP3 antibody. Medium from three parallel wells per siRNA
are shown (lanes 1–3 and 4–6, respectively) in addition to untreated
cells showing the induction of MMP3 in the presence of PMA
(compare lanes 7 and 8). The levels of b-actin in the cells from which
the medium were harvested are shown in the lower panel. The cells in
each well were harvested in 30ml2   SDS loading buﬀer and the extract
separated by SDS–PAGE (10%). (B) Knockdown of endogenous SPBP
reduces the MMP3 secretion in PMA-stimulated IMR90 cells by 50%.
The amount of secreted MMP3 was normalized to the level of b-actin
expression in each well. Quantiﬁcation was performed using the
LumiAnalyst software (Roche). A western blot of SPBP expression in
total cellular extract from IMR90 cells transfected with scrambled
siRNA and SPBP siRNA are shown in the inserted panel.
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not dependent on this SPRE element since: (i) mutation of
the tandem EBS in the MMP3 promoter inhibited the
stimulatory eﬀect of SPBP; (ii) the MMP3 promoter
construct used in this study (containing 1448bp of the
MMP3 upstream region) does not include the SPRE
element; (iii) a MMP3 promoter construct containing the
SPRE site (2298bp of the MMP3 upstream region) gave
similar results as the 1448bp construct (data not shown)
and (iv) no such SPRE element has been identiﬁed in the
c-myc P1P2 promoter.
We found that SPBP, TopBP1 and Ets1 are all
associated with a short fragment of the MMP3 promoter,
and that SPBP and TopBP1 interacts in vivo. However, we
have not been able to co-immunoprecipitate endogenous
Ets1 and SPBP, or endogenous Ets1 and TopBP1,
suggesting that any physical interactions between Ets1
and these two proteins are weak and/or may be dependent
on an unknown factor. Hence, the mechanism for SPBP
and TopBP1-mediated stimulation of Ets1 has to be
elucidated. At least three mechanistic models can be
suggested. First, SPBP contains a DNA-binding domain
with an AT-hook motif which binds sequence speciﬁcally
to AT-rich DNA-binding motifs (1). The EBS in the
MMP3-promoter and the P1P2c-myc promoter are
ﬂanked with AT-rich sequences. Hence, SPBP may
recognize these sequences, and when Ets1 is bound at a
proximal site, the binding of both proteins is stabilized.
Other transcription factors have been shown to modulate
the DNA-binding aﬃnity of Ets1, and thereby regulate its
transcriptional activity (44). The Ets1–SPBP–DNA com-
plex may recruit oligomerized TopBP1 to the promoter via
the ePHD domain of SPBP. Second, PHD domains are
known to contain nucleosome-binding activity (7), speci-
ﬁcally recognizing methylated histone tails (8). Hence,
SPBP may be recruited to the promoter sites via its ePHD
domain. The ePHD domain which also contains protein-
binding activity (7), may recruit or stabilize Ets1 and
TopBP1at the promoters. Third, SPBP may relocalize
TopBP1 from repressor complexes. It is shown that E2F1
and Ets1 compete for the same binding site in the P1P2
c-myc promoter (45,46). E2F1 represses expression from
the c-myc promoter (45), while Ets1 act as an activator
(46,47). TopBP1 binds to E2F1 and repress its activity
(16). Thus, SPBP associated with Ets1 may recruit
TopBP1 from the repressive E2F1–TopBP1 complexes to
Figure 7. The SPBP homologue RAI1 does not stimulate Ets1-mediated
transcriptional activation of the MMP3 promoter or co-operate with
TopBP1. (A) TopBP1 potentiates the SPBP-enhanced Ets1 transactiva-
tion in a dose-dependent manner. Transient transfections were carried out
in HeLa cells as described in Figure 4 except that 0.5mg of the SPBP
expression plasmid and increasing amounts of TopBP1 expression
plasmids (0.5, 1.0 and 1.5mg, respectively) were used. The data represent
the mean of two individual experiments performed in triplicate. (B) RAI1
does not enhance Ets1 transactivation or act together with TopBP1 to
enhanceEts1-mediatedtranscription.Transienttransfectionswerecarried
out in HeLa cells as described in (A) except that 0.5mg or 1.0mg of RAI1
expression plasmid was used instead of the SPBP expressing plasmid. The
data represent the mean of two individual experiments performed in
triplicate. (C) Western blot documenting similar expression levels of HA-
SPBPand HA-RAI1 in HeLa cells. Total cellular extractsfrom HeLacells
transfected with expression plasmids for HA-RAI1 or HA-SPBP as
indicated were analysed by 6% SDS–PAGE and immunoblotted using an
anti-HA antibody. (D) Yeast two-hybrid assay showing that the ePHD
domain of RAI1 interacts very weakly with TopBP1 compared to the
SPBP ePHD domain, and the ePHD domains of MML protein family.
One colony containing AD or DBD plasmids was picked and
re-suspended 200mld H 2O. Ten microlitres of the cell suspension was
spotted on QDO medium and allowed to grow at 308C for 3 days.
Nucleic Acids Research, 2007, Vol. 35, No. 19 6659the stimulatory co-operation of Ets1, SPBP and TopBP1,
and thereby switch the regulation of the P1P2c-myc
promoter from oﬀ to on. It is reported that Akt/PKB
induces expression of c-myc (48). This is in line with our
results showing that stimulation of the P1P2c-myc
promoter by Ets1, SPBP and TopBP1 is dependent on
the S1159 phosphorylation site of TopBP1 shown to be an
Akt/PKB substrate (20).
SPBP is found to be 4- to 6-fold up-regulated in
arthrinogenic synovial ﬁbroblasts (49), which are the cells
mainly responsible for hyperplasia and chronic inﬂamma-
tion in rheumatoid arthritis. Activated ﬁbroblast-like
synoviocytes (FLS) are characterized by an up-regulated
expression of adhesion molecules, chemokines, proinﬂam-
matory molecules, oncogenes and matrix metalloprotei-
nases (50). Interestingly, both c-myc (51) and MMP3 (52)
are shown to be extensively expressed in FLSs. Hence,
SPBP expression correlates well with c-myc and MMP3
expression, and also with the invasive properties of the
FLSs. Furthermore, two recent papers show that MMP3
expression is induced via the PI3K/Akt pathway
in ﬁbroblasts (53) and microglia (54). These reports
correspond well with our results showing that the more
than additive enhancement of the MMP3 promoter by
SPBP and TopBP1 is abolished if a S1159A mutant of
TopBP1 is co-expressed with SPBP. FLS exhibit char-
acteristics of metastatic cells, such as decreased adhesion,
increased proliferation and migration. Interestingly, SPBP
expression is shown to be up-regulated in small-cell lung
cancer and advanced adenocarcinoma cells from patients
receiving extensive chemotherapy treatment (55) and in
desmoid tumours (56). Hence, together with our data
these results suggest that a co-operation between SPBP
and TopBP1 may contribute to the metastatic process by
up-regulating c-myc and MMP3 expression.
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